This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CNAT vs. VRPX, SCPS, ARDS, EVLO, CMRA, STAB, AMPE, PXMD, CALA, and CLVRShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), PaxMedica (PXMD), Calithera Biosciences (CALA), and Clever Leaves (CLVR). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. Its Competitors Virpax Pharmaceuticals Scopus BioPharma Aridis Pharmaceuticals Evelo Biosciences Comera Life Sciences Statera Biopharma Ampio Pharmaceuticals PaxMedica Calithera Biosciences Clever Leaves Conatus Pharmaceuticals (NASDAQ:CNAT) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk. Is CNAT or VRPX more profitable? Virpax Pharmaceuticals has a net margin of 0.00% compared to Conatus Pharmaceuticals' net margin of -52.42%. Conatus Pharmaceuticals' return on equity of -48.22% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Conatus Pharmaceuticals-52.42% -48.22% -39.32% Virpax Pharmaceuticals N/A -1,554.34%-338.29% Which has preferable valuation and earnings, CNAT or VRPX? Conatus Pharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConatus Pharmaceuticals$21.72M0.00-$11.39MN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Do insiders and institutionals hold more shares of CNAT or VRPX? 15.2% of Conatus Pharmaceuticals shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 11.3% of Conatus Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer CNAT or VRPX? In the previous week, Conatus Pharmaceuticals' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score. Company Overall Sentiment Conatus Pharmaceuticals Neutral Virpax Pharmaceuticals Neutral Do analysts recommend CNAT or VRPX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conatus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, CNAT or VRPX? Conatus Pharmaceuticals has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. SummaryConatus Pharmaceuticals beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks. Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$10K$848.51M$5.78B$9.80BDividend YieldN/A4.84%3.95%4.01%P/E Ratio0.001.1122.5622.49Price / Sales0.0026.55463.84113.07Price / CashN/A19.5637.7359.36Price / Book0.006.7310.046.68Net Income-$11.39M-$4.20M$3.27B$265.59M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.00flatN/A-99.9%$10K$21.72M0.0030VRPXVirpax PharmaceuticalsN/A$0.01flatN/A-99.9%$14KN/A0.007SCPSScopus BioPharmaN/A$0.00flatN/A+66.7%$13KN/A0.009ARDSAridis PharmaceuticalsN/A$0.00+100.0%N/AN/A$11KN/A0.0030Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002STABStatera BiopharmaN/A$0.00flatN/A-66.7%$5KN/A0.0020Gap UpAMPEAmpio PharmaceuticalsN/A$0.00flatN/A+3,695.5%$3KN/A0.0020PXMDPaxMedicaN/A$0.00flatN/A-99.9%$2KN/A0.002CALACalithera Biosciences0.5452 of 5 stars$0.00-80.0%N/AN/A$1KN/A0.0060CLVRClever LeavesN/A$0.00flatN/A+0.0%$1K$17.42M0.00560Gap Up Related Companies and Tools Related Companies Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Aridis Pharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors PaxMedica Competitors Calithera Biosciences Competitors Clever Leaves Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNAT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access